Skip to main content
. 2021 Oct 18;37(1):168–175. doi: 10.1007/s11606-021-07146-0

Table 2.

Symptoms and Physical Examination Upon Admission

All cohort Matched-cohort
CS CS+TCZ p value CS CS+TCZ p value
Cough, n (%) 3677 (69) 485 (79.8) <0.001 434 (71.5) 485 (79.8) 0.001
Arthromyalgias, n (%) 1425 (26.7) 211 (34.7) <0.001 182 (30) 211 (34.7) 0.079
Ageusia, n (%) 574 (10.8) 71 (11.7) 0.493 88 (14.5) 71 (11.7) 0.145
Anosmia, n (%) 484 (9.1) 68 (11.2) 0.090 69 (11.4) 68 (11.2) 0.920
Sore throat, n (%) 428 (8) 72 (11.8) 0.001 69 (11.4) 72 (11.8) 0.796
Headache, n (%) 608 (11.4) 96 (15.8) 0.002 74 (12.2) 96 (15.8) 0.071
Fever, n (%) 4118 (77.2) 523 (86) <0.001 505 (83.2) 523 (86) 0.173
Dyspnea, n (%) 3625 (68) 433 (71.2) 0.105 434 (71.5) 433 (71.2) 0.913
Diarrhea, n (%) 1231 (23.1) 181 (29.8) <0.001 163 (26.9) 181 (29.8) 0.259
Vomiting, n (%) 360 (6.8) 44 (7.2) 0.653 42 (6.9) 44 (7.2) 0.829
Abdominal pain, n (%) 285 (5.3) 34 (5.6) 0.798 30 (4.9) 34 (5.6) 0.612
Heart rate, bpm median [IQR] 87 [76–100] 91 [80–104] <0.001 90 [80–101] 91 [80–104] 0.079
Respiratory rate >20 rpm, n (%) 2109 (39.6) 328 (53.9) <0.001 314 (51.7) 328 (53.9) 0.439

IQR interquartile range, CS corticosteroids, CS+TCZ corticosteroids + tocilizumab